References
- U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER): Guidance for Industry, Estrogen and Estrogen/Progestin Drug Products to Treat Vasomotor Symptoms and Vulvar and Vaginal Atrophy Symptoms – Recommendations for Clinical Evaluation. DRAFT January 2nd 2003. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm071643.pdf (accessed 2011-01-03)
- European Medicines Agency (EMA), Committee for Medicinal Products for Human Use (CHMP): Guideline on Clinical Investigation of Medicinal Products for Hormone Replacement Therapy of Oestrogen Deficiency Symptoms in Postmenopausal Women. London, 13 October 2005 Doc. Ref. EMEA/CHMP/021/97 Rev. 1 http://www.ema.europa.eu/pdfs/human/ewp/002197en.pdf (accessed 2011-01-03)
- Kurman RJ, ed. Blaustein's Pathology of the Female Genital Tract, 5th. New York: Springer, 2002
- Gerlinger C, Endrikat J, van der Meulen EA, Dieben TOM, Düsterberg B. Recommendation for confidence interval and sample size calculation for the Pearl Index. Eur J Contracept Reprod Health Care 2003;8:87–92
- Hartung J. Statistik, 13th. München: Oldenbourg Wissenschaftsverlag GmbH, 2002
- Kalbfleisch JD, Prentice RL. The Statistical Analysis of Failure Time Data. New York: John Wiley & Sons, Inc, 1980
- Johnson NL, Kotz S, Kemp AW. Univariate Discrete Distributions, 2nd. New York: Wiley, 1993:130, formula 3.81
- Benda N, Gerlinger C, van der Meulen EA, Endrikat J. Sample size calculation for clinical studies on the efficacy of a new contraceptive method. Biometrical J 2004;46:141–50
- Schwenke C, Busse R. Analysis of differences in proportions from clustered data with multiple measurements in diagnostic studies. Methods Inform Med 2007;46:548–52
- www.ich.org (accessed 2011-01-03)